基于网络药理学方法探讨犀角地黄汤治疗系统性红斑狼疮的作用机制

doi:10.5246/jcps.2023.05.030

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (5): 351-359.DOI: 10.5246/jcps.2023.05.030

基于网络药理学方法探讨犀角地黄汤治疗系统性红斑狼疮的作用机制

王孟亚¹, 张宽友², 陈馨¹, 付浩¹^,^*(), 彭守春³^,^*()

1. 武警特色医学中心, 天津 300162
2. 天津市河东区东新街社区卫生服务中心, 天津 300162
3. 天津市海河医院, 天津 300350

收稿日期:2022-11-23 修回日期:2022-12-04 接受日期:2023-01-15 出版日期:2023-06-02 发布日期:2023-06-02
通讯作者: 付浩, 彭守春
作者简介:
+ Tel.: +86-22-61122977, E-mail: fuhaoyxs@163.com
+ Tel.: +86-22-60577216, E-mail: pengshouchun@163.com
基金资助:
The Scientific Research Projects of PLA (Grant No. 21JSZ23); Research Project of PAP (Grant No. CWJ18L004).

Study on the mechanism of Rhinoceros Horn and Rehmannia Decoction in the treatment of systemic lupus erythematosus based on the method of network pharmacology

Mengya Wang¹, Kuanyou Zhang², Xin Chen¹, Hao Fu¹^,^*(), Shouchun Peng³^,^*()

1 Characteristic Medical Center of PAP, Tianjin 300162, China
2 Dongxin Street Community Health Service Center, Hedong District, Tianjin 300162, China
3 Haihe Hospital, Tianjin 300350, China

Received:2022-11-23 Revised:2022-12-04 Accepted:2023-01-15 Online:2023-06-02 Published:2023-06-02
Contact: Hao Fu, Shouchun Peng

摘要/Abstract

摘要：

本研究通过网络药理学方法, 探讨犀角地黄汤治疗系统性红斑狼疮(SLE)的作用机制。首先通过TCMSP、TCMID和BATMAN-TCM数据库检索犀角地黄汤各中药成分的活性成分及其靶点, 汇总得到药物靶点; 其次在CTD、OMIM和TCMIP数据库检索得到SLE的疾病靶点, 并对药物靶点和疾病靶点的交集进行分析。利用Cytoscape 3.7.1软件构建药物-成分-靶点-疾病网络。在String平台构建治疗靶点的蛋白质互作网络(PPI), 筛选其关键模块和Hub基因, 在DAVID数据库进行GO和KEGG富集分析。最终筛选出22个犀角地黄汤的活性成分, 209个药物靶点, 284个疾病靶点, 59个治疗靶点。药物-成分-靶点-疾病网络和PPI网络分析得到槲皮素、山奈酚、黄芩素等核心活性成分, PTGS2、CASP3、MMP9、AKT1、JUN、CXCL8、FOS、TP53等核心靶点。主要涉及TNF、PI3K-Akt、Toll样受体、T细胞受体、细胞凋亡等信号通路。研究表明犀角地黄汤可能通过调控炎症、免疫及细胞凋亡等信号通路, 发挥抗炎、抑制异常免疫应答和细胞凋亡的作用, 具有多中心、多靶点、多途径的特点。

关键词: 系统性红斑狼疮, 网络药理学, 犀角地黄汤, 靶点

Abstract:

In the present study, we aimed to explore the mechanism of Rhinoceros Horn and Rehmannia Decoction in treating systemic lupus erythematosus (SLE). First, the active ingredients and their targets of the Chinese medicine components of Rhinoceros Horn and Rehmannia Decoction were searched through TCMSP, TCMID, and BATMAN-TCM databases, and then the drug targets were summarized. Then the disease targets of SLE were retrieved from CTD, OMIM, and TCMIP databases, and the intersection of drug targets and disease targets was analyzed. Cytoscape 3.7.1 software was used to construct a drug-component target-disease network. The protein-protein interaction (PPI) network of therapeutic targets was constructed on the String platform, and its key modules and hub genes were screened. GO and KEGG enrichment analyses were performed in the DAVID database. A total of 22 active ingredients, 209 drug targets, 284 disease targets, and 59 therapeutic targets were screened out. Drug-component-target-disease and PPI network analysis yielded core active ingredients, such as quercetin, kaempferol, and baicalein, and core targets, such as PTGS2, CASP3, MMP9, AKT1, JUN, CXCL8, FOS, and TP53. It mainly involves TNF, PI3K Akt, Toll-like receptor, T cell receptor, and apoptosis signal pathways. It can be seen that Rhinoceros Horn and Rehmannia Decoction may play the role of anti-inflammation, inhibition of abnormal immune response, and apoptosis by regulating inflammation, immunity, and apoptosis signaling pathways. It has the characteristics of multi-center, multi-target, and multi-pathway.

Key words: Systemic lupus erythematosus, Network pharmacology, Rhinoceros Horn and Rehmannia Decoction, Target

Supporting:

王孟亚, 张宽友, 陈馨, 付浩, 彭守春. 基于网络药理学方法探讨犀角地黄汤治疗系统性红斑狼疮的作用机制[J]. 中国药学(英文版), 2023, 32(5): 351-359.

Mengya Wang, Kuanyou Zhang, Xin Chen, Hao Fu, Shouchun Peng. Study on the mechanism of Rhinoceros Horn and Rehmannia Decoction in the treatment of systemic lupus erythematosus based on the method of network pharmacology[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 351-359.

图/表 5

Table 1. Active ingredients of Rhinoceros Horn and Rehmannia Decoction.

Figure 1. DCTDN of Rhinoceros Horn and Rehmannia Decoction for SLE.

Figure 2. PPI network diagram of the therapeutic target, key modules, and hub genes. (A) PPI network of treatment target; (B) PPI network key module, the inner level degree value is 40–51, and the outer layer’s degree value is 29–39; (C) Hub gene of crucial modules.

Figure 3. Venn diagram of drug component target disease network and hub gene.

Figure 4. Analysis of gene function enrichment. A: GO analysis diagram; B: KEGG enrichment bubble diagram.

参考文献 24

[1]	Barnett, R. Systemic lupus erythematosus. Lancet. 2016, 387, 1711.
[2]	Chen, W.W.; Xiao, X.L.; Su, L.; Su, X.; Xia, J. Compound Shengdi Mixture from TLR-NF- κ B pathway regulates Th17/Treg balance in MRL/lpr mice. Chin. J. Tradit. Chin. Med. 2020, 10, 5270–5273.
[3]	Zhu, Y.L.; Wu, F. Overview of TCM syndrome types and changes of systemic lupus erythematosus. Chin. J. Tradit. Chin. Med. 2018, 07, 2973–2975.
[4]	Jiang, Z.; Tang, F.; Ma, W.K.; Lan, W.Y.; Fan, M.; Cai, X. Meta analysis of the clinical efficacy of Rhinoceros horn Rehmannia glutinosa decoction combined with anti rheumatic drugs in the treatment of heat toxic and intense systemic lupus erythematosus. J. Guizhou Univ. Tradit. Chin. Med. 2021, 03, 81–87.
[5]	Zhou, G.W.; Chen, Y.H.; Xia, P.; Gao, K.; Chen, J.M.; Guo, F. Study on the mechanism of Langchuangjing traditional Chinese medicine granules in treating systemic lupus erythematosus based on network pharmacology. Chin. J. Tradit. Chin. Med. 2020, 10, 122–127.
[6]	Fei, X.J.; Zhang, X.; Wang, Q.; Li, J.B.; Shen, H.; Wang, X.Y.; Liu, H.Q.; Tao, W.W. Xijiao Dihuang Decoction alleviates ischemic brain injury in MCAO rats by regulating inflammation, neurogenesis, and angiogenesis. Evid. Based Complement. Altern. Med. 2018, 2018, 5945128.
[7]	Liu, J.; Pei, T.; Mu, J.; Zheng, C.; Chen, X.; Huang, C.; Fu, Y.; Liang, Z.; Wang, Y. Systems Pharmacology Uncovers the Multiple Mechanisms of Rhinoceros horn Rehmannia glutinosa Decoction for the Treatment of Viral Hemorrhagic Fever. Evid. Based Complement. Altern. Med. 2016, 06, 9025036.
[8]	Huang, D.Y. Effect of Rhinoceros horn Rehmannia glutinosa Decoction on inflammatory factors and immunoglobulin in patients with systemic lupus erythematosus skin damage. Modern Med. Health Res. Elect. J. 2020, 08, 71–73.
[9]	Wang, F.S. Clinical efficacy of Rhinoceros horn Rehmannia glutinosa decoction combined with small dose of corticosteroids in the treatment of heat toxic and burning systemic lupus erythematosus. J. Pract. Chin. Med. 2021, 04, 100–102.
[10]	Zhou, X.G.; Li, H.W.; Wu, J.L. Effect of quercetin on LPE like mouse model induced by hypoglycane. Chin. J. Hospital Pharm. 2016, 21, 1869–1872.
[11]	Cheng, L.Y.; Tu, L.L.; Shi, H. p38MAPK’s effect on chronic prostatitis pain and the intervention of quercetin. China Modern Appl. Pharm. 2016, 08, 984–988.
[12]	Lin, F. Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation. Int. Immunopharmacol. 2015, 28, 859–865.
[13]	Ma, S.; Jin, Y.; Shi, Y.; Zhang, Y.D. Study on the effect of Hongban Qingtang on sIL-2R level and prognosis of patients with systemic lupus erythematosus. Sichuan Tradit. Chin. Med. 2019, 08, 141–143.
[14]	Kordulewska, N.K.; Cieślińska, A.; Fiedorowicz, E.; Jarmołowska, B.; Kostyra, E. High expression of IL-1RI and EP2 receptors in the IL-1β/COX-2 pathway, and a new alternative to non-steroidal drugs—osthole in inhibition COX-2. Int. J. Mol. Sci. 2019, 20, 186.
[15]	Chen, S.; Wang, Y.; Qin, H.; Lin, J.; Xie, L.; Chen, S.; Liang, J.; Xu, J. Downregulation of miR-633 activated AKT/mTOR pathway by targeting AKT1 in lupus CD4⁺ T cells. Lupus. 2019, 28, 510–519.
[16]	Ruchakorn, N.; Ngamjanyaporn, P.; Suangtamai, T.; Kafaksom, T.; Polpanumas, C.; Petpisit, V.; Pisitkun, T.; Pisitkun, P. Performance of cytokine models in predicting SLE activity. Arthritis Res. Ther. 2019, 21, 287.
[17]	Yu, Y.; Liu, L.; Hu, L.L.; Yu, L.L.; Li, J.P.; Rao, J.A.; Zhu, L.J.; Liang, Q.; Zhang, R.W.; Bao, H.H.; Cheng, X.S. Potential therapeutic target genes for systemic lupus erythematosus: a bioinformatics analysis. Bioengineered. 2021, 12, 2810–2819.
[18]	Oikonomidou, O.; Vlachoyiannopoulos, P.G.; Kominakis, A.; Kalofoutis, A.; Moutsopoulos, H.M.; Moutsatsou, P. Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-Jun N-terminal kinase in systemic lupus erythematosus patients. Neuroimmunomodulation. 2006, 13, 194–204.
[19]	Schonthaler, H.B.; Guinea-Viniegra, J.; Wagner, E.F. Targeting inflammation by modulating the Jun/AP-1 pathway. Transl. Psychiatry. 2011, 70, i109–i112.
[20]	Yang, Z.; Xie, R.F.; Zhong, M.H.; Xie, G.Q.; Fan, Y.S.; Zhao, T. Potential molecular mechanisms of Zhibai Dihuang wan in systemic lupus erythematosus based on network biology. Evid. Based Complement. Altern. Med. 2020, 2020, 7842179.
[21]	Teng, Z.; Lin, X.; Luan, C.; Sun, Y.; Li, X. The high expression of miR-564 in patients with systemic lupus erythematosus promotes differentiation and maturation of DC cells by negatively regulating TP53 expression in vitro. Lupus. 2021, 30, 1469–1480.
[22]	Zhou, Y.; Li, Z. Systemic lupus erythematosus and infection. Chin. J. Clin. (Electronic Edition). 2016, 21, 3271–3275.
[23]	Gong, X.B.; Li, H.; Li, SW.; Wang, B.S.; Yao, M.M. Network Pharmacological Analysis of Artemisia Annua in Treating Systemic Lupus Erythematosus. J. Clin. Chin. Med. 2021, 06, 1112–1118.
[24]	Li, J.; Wang, X.; Zhang, F.; Yin, H. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacol. Ther. 2013, 138, 441–451.

基于网络药理学方法探讨犀角地黄汤治疗系统性红斑狼疮的作用机制

Study on the mechanism of Rhinoceros Horn and Rehmannia Decoction in the treatment of systemic lupus erythematosus based on the method of network pharmacology

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴梦瑶, 刘璐, 张鹏, 张乐乐, 龚云, 杨秀伟. 基于网络药理学和实验验证研究补血益母丸治疗产后腹痛的作用机制[J]. 中国药学(英文版), 2023, 32(9): 691-703.
[2]	尚平, 刘琳, 方毅. 基于网络药理学和分子对接探讨桂枝茯苓丸治疗子宫内膜异位症的作用机制[J]. 中国药学(英文版), 2023, 32(9): 704-719.
[3]	张格第, 刘庚鑫, 晏子友. 基于meta分析和网络药理学理冲汤(丸)治疗癌症的疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(9): 720-735.
[4]	武东燕, 王小丹, 柴金苗, 李钦青, 李悦, 毕梅, 桂婉威, 曹慧敏. 基于网络药理学及实验验证探究当归补血汤治疗糖尿病性视网膜病变的作用机制[J]. 中国药学(英文版), 2023, 32(7): 527-538.
[5]	闫焕, 王健, 付浩, 杨敏, 曲苗, 方志娥. 基于网络药理学探讨大柴胡汤治疗高脂血症的潜在作用靶点和机制[J]. 中国药学(英文版), 2023, 32(6): 446-459.
[6]	沈广志, 崔新刚, 那志敏, 邹玉龙, 邹桂华. 利用网络药理学探究淫羊藿治疗性功能障碍的药理作用机制[J]. 中国药学(英文版), 2023, 32(5): 379-391.
[7]	敖民, 包明兰, 侯亚星, 月英, 李慧芳, 吴国华, 苏日嘎拉图. 基于网络药理学的蒙药肋柱花抗急性肝损伤作用机制研究[J]. 中国药学(英文版), 2023, 32(4): 268-282.
[8]	李雅静, 白雅雯, 杜宇, 严长宏, 麻春杰, 孙丽宁, 卜凤跃, 严昊阳. 玉屏风散治疗慢性肾小球肾炎的临床疗效评价及作用机制研究[J]. 中国药学(英文版), 2023, 32(12): 1006-1026.
[9]	孙志勇, 高淑丽, 张阳, 薛刚强, 苑子林, 王少男. 基于网络药理学和分子对接技术研究蒲公英治疗乳腺增生的潜在机制[J]. 中国药学(英文版), 2023, 32(11): 893-910.
[10]	张玉倩, 牛海英, 靳怡然. 基于网络药理学技术探讨长春花治疗癌症的作用机制[J]. 中国药学(英文版), 2023, 32(11): 911-922.
[11]	周代英, 陈靓, 吕志刚. 基于网络药理学和分子对接探讨灯盏细辛治疗年龄相关性黄斑变性的机制[J]. 中国药学(英文版), 2023, 32(11): 923-934.
[12]	魏东升, 刘孝生, 李路珍, 齐佳杰, 王雨轩, 张哲. 基于综合生物信息学和单细胞测序方法揭示红花-丹参治疗冠心病的生物学和免疫学机制[J]. 中国药学(英文版), 2023, 32(10): 796-812.
[13]	丁宁, 张涛, 罗吉, 刘皓辰, 邓宇, 何永恒. 基于网络药理学和分子对接探究白芍七物汤治疗结直肠癌的作用机制[J]. 中国药学(英文版), 2023, 32(1): 17-31.
[14]	伊帕尔古丽·阿皮孜, 王昭志, 贺宏吉, 李喆喆, 王梅. 基于网络药理学和分子对接探讨骆驼蓬种子抗肝癌作用机制[J]. 中国药学(英文版), 2022, 31(7): 517-529.
[15]	赵维萍, 葛奇, 丁子俊, 潘雷枝, 谷子晴, 刘洋, 蔡华. 基于网络药理学和代谢组学分析滁菊中潜在活性成分及其药理作用机制[J]. 中国药学(英文版), 2022, 31(6): 412-428.